↑ 薬物リストへ　← 戻る

Dosing interruption of natalizumab    (DrugBank: Natalizumab)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
13多発性硬化症／視神経脊髄炎1

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：3,050，薬物数：2,147（DrugBank：348），標的遺伝子数：244，標的パスウェイ数：228］
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04048577
(ClinicalTrials.gov)		July 3, 201915/4/2019A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of NatalizumabThe Impact of a Planned 12-week Dosing Interruption of Natalizumab on Immune Cell Trafficking, Pharmacokinetic (PK)/Pharmacodynamic (PD) Parameters, and Multiple Sclerosis (MS) Disease Stability.Multiple Sclerosis;Multiple Sclerosis, Relapsing-RemittingDrug: Dosing Interruption of NatalizumabBerkovich, Regina MD, PhD Inc.Biogen;Cedars-Sinai Medical CenterRecruiting21 Years65 YearsAll10Phase 4United States